- Thermo Fisher Scientific Inc. is growing its oral solid dose (OSD) capabilities with a $22 million investment across its Cincinnati, Ohio, and Bend, Oregon sites, an initiative that has been underway since 2021.
- The investment supports advanced R&D, manufacturing, and testing of OSD drug formulations to meet growing industry demand.
Thermo Fisher Scientific has announced a $22-million investment across its Cincinnati, Ohio, and Bend, Oregon facilities to expand their oral solid dose (OSD) capabilities. The move, initiated in 2021, aims to enhance the research, development, manufacturing, and testing of OSD drug formulations, which account for 84% of all medications on the market. This investment is part of the company’s broader effort to strengthen its global CDMO and CRO network.
The Cincinnati site will benefit from new R&D space dedicated to pre-clinical development, enabling faster project initiation and leveraging next-generation technologies for data-driven decision-making. In Bend, the expansion will focus on advanced manufacturing and testing, including spray drying and hot-melt extrusion, aimed at addressing solubility and bioavailability challenges for pharma and biotech clients.
Michelle Logan, Vice President and General Manager of Drug Product North America at Thermo Fisher, stated, “Expanding our capabilities in North America builds services in OSD formulations to help ensure that our customers can develop and commercialize accessible, life-saving therapies.”
These enhancements are set to accelerate pre-clinical drug product development and reduce timelines to GMP production for clinical trials, providing much-needed support for pharmaceutical and biotech companies navigating early-stage development.
Overview of outsourcing trends 
